First Time Loading...

Ulisse Biomed Spa
MIL:UBM

Watchlist Manager
Ulisse Biomed Spa Logo
Ulisse Biomed Spa
MIL:UBM
Watchlist
Price: 1.2 EUR -2.44%
Updated: May 21, 2024

Intrinsic Value

Ulisse BioMed SpA is an Italian healthcare biotech company. [ Read More ]

The intrinsic value of one UBM stock under the Base Case scenario is 0.05 EUR. Compared to the current market price of 1.2 EUR, Ulisse Biomed Spa is Overvalued by 96%.

Key Points:
UBM Intrinsic Value
Base Case
0.05 EUR
Overvaluation 96%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Ulisse Biomed Spa

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling UBM stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ulisse Biomed Spa

Provide an overview of the primary business activities
of Ulisse Biomed Spa.

What unique competitive advantages
does Ulisse Biomed Spa hold over its rivals?

What risks and challenges
does Ulisse Biomed Spa face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ulisse Biomed Spa.

Provide P/S
for Ulisse Biomed Spa.

Provide P/E
for Ulisse Biomed Spa.

Provide P/OCF
for Ulisse Biomed Spa.

Provide P/FCFE
for Ulisse Biomed Spa.

Provide P/B
for Ulisse Biomed Spa.

Provide EV/S
for Ulisse Biomed Spa.

Provide EV/GP
for Ulisse Biomed Spa.

Provide EV/EBITDA
for Ulisse Biomed Spa.

Provide EV/EBIT
for Ulisse Biomed Spa.

Provide EV/OCF
for Ulisse Biomed Spa.

Provide EV/FCFF
for Ulisse Biomed Spa.

Provide EV/IC
for Ulisse Biomed Spa.

Show me price targets
for Ulisse Biomed Spa made by professional analysts.

Compare the intrinsic valuations
of Ulisse Biomed Spa and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ulisse Biomed Spa against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ulisse Biomed Spa compared to its peers.

Compare the P/E ratios
of Ulisse Biomed Spa against its peers.

Discuss the investment returns and shareholder value creation
comparing Ulisse Biomed Spa with its peers.

Analyze the financial leverage
of Ulisse Biomed Spa compared to its main competitors.

Show all profitability ratios
for Ulisse Biomed Spa.

Provide ROE
for Ulisse Biomed Spa.

Provide ROA
for Ulisse Biomed Spa.

Provide ROIC
for Ulisse Biomed Spa.

Provide ROCE
for Ulisse Biomed Spa.

Provide Gross Margin
for Ulisse Biomed Spa.

Provide Operating Margin
for Ulisse Biomed Spa.

Provide Net Margin
for Ulisse Biomed Spa.

Provide FCF Margin
for Ulisse Biomed Spa.

Show all solvency ratios
for Ulisse Biomed Spa.

Provide D/E Ratio
for Ulisse Biomed Spa.

Provide D/A Ratio
for Ulisse Biomed Spa.

Provide Interest Coverage Ratio
for Ulisse Biomed Spa.

Provide Altman Z-Score Ratio
for Ulisse Biomed Spa.

Provide Quick Ratio
for Ulisse Biomed Spa.

Provide Current Ratio
for Ulisse Biomed Spa.

Provide Cash Ratio
for Ulisse Biomed Spa.

What is the historical Revenue growth
over the last 5 years for Ulisse Biomed Spa?

What is the historical Net Income growth
over the last 5 years for Ulisse Biomed Spa?

What is the current Free Cash Flow
of Ulisse Biomed Spa?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ulisse Biomed Spa.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ulisse Biomed Spa

Current Assets 4.2m
Cash & Short-Term Investments 2.9m
Receivables 991.5k
Other Current Assets 326.1k
Non-Current Assets 1.5m
Long-Term Investments 6.1k
PP&E 119.8k
Intangibles 1.4m
Other Non-Current Assets 10
Current Liabilities 277.4k
Accounts Payable 156.7k
Other Current Liabilities 120.7k
Non-Current Liabilities 421.1k
Other Non-Current Liabilities 421.1k
Efficiency

Earnings Waterfall
Ulisse Biomed Spa

Revenue
90.9k EUR
Cost of Revenue
-1.1m EUR
Gross Profit
-967.9k EUR
Operating Expenses
-707.6k EUR
Operating Income
-1.7m EUR
Other Expenses
-190 EUR
Net Income
-1.7m EUR

Free Cash Flow Analysis
Ulisse Biomed Spa

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

UBM Profitability Score
Profitability Due Diligence

Ulisse Biomed Spa's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

Negative 1-Year Revenue Growth
Negative Operating Income
Negative Net Income
Negative ROE
13/100
Profitability
Score

Ulisse Biomed Spa's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

UBM Solvency Score
Solvency Due Diligence

Ulisse Biomed Spa's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Ulisse Biomed Spa's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

UBM Price Targets Summary
Ulisse Biomed Spa

Wall Street analysts forecast UBM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UBM is 1.9 EUR .

Lowest
Price Target
Not Available
Average
Price Target
1.9 EUR
58% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Competitors Analysis
Ulisse Biomed Spa

Shareholder Return

UBM Price
Ulisse Biomed Spa

1M 1M
-2%
6M 6M
-26%
1Y 1Y
-38%
3Y 3Y
-70%
5Y 5Y
-70%
10Y 10Y
-70%
Annual Price Range
1.2
52w Low
1.1
52w High
2.23
Price Metrics
Average Annual Return -43.28%
Standard Deviation of Annual Returns 36.06%
Max Drawdown -84%
Shares Statistics
Market Capitalization 26.2m EUR
Shares Outstanding 21 804 770
Percentage of Shares Shorted
N/A

UBM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Ulisse Biomed Spa Logo
Ulisse Biomed Spa

Country

Italy

Industry

Biotechnology

Market Cap

26.2m EUR

Dividend Yield

0%

Description

Ulisse BioMed SpA is an Italian healthcare biotech company. The company is headquartered in Udine, Udine. The company went IPO on 2021-08-06. The firm focuses on creating new and transformative diagntostic platforms and products. The company creates diagnostic systems that can reach people directly and help increasing the frequency of health monitoring. Its platforms include Sagitta, NanoHybrid and Aptavir. Sagitta is a molecular diagnostics technology platform, capable of detecting and characterizing nucleic acids of viral, bacterial and eukaryotic origin. Sagitta is used to develop assays for Respiratory Viral Panel, Sexually Transmitted Diseases, Infectious Diseases and Oncology. NanoHybrid can be implemented not only to develop diagnostic solutions but also in the field of theranostics: the integration of a diagnostic method with a specific therapeutic intervention aimed at maximizing the effectiveness of the drug, as well as vaccine/immunoterapies monitoring. Aptavir is a platform for the identification and production of antiviral molecules.

Contact

UDINE
Udine
Via Cavour 20
+390403757540
http://ulissebiomed.com

IPO

2021-08-06

Employees

-

Officers

CEO & Director
Mr. Nicola Basile
Co-founder, COO & Executive Director
Ms. Bruna Marini
Co-Founder & Chief Scientific Officer
Mr. Rudy Ippodrino
Head of Business Development
Mr. Ferdinando Giuliani
Executive Director
Mr. Carlo Montenovesi

See Also

Discover More
What is the Intrinsic Value of one UBM stock?

The intrinsic value of one UBM stock under the Base Case scenario is 0.05 EUR.

Is UBM stock undervalued or overvalued?

Compared to the current market price of 1.2 EUR, Ulisse Biomed Spa is Overvalued by 96%.